Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Carl Blomqvist, Inkeri Elomaa, Pentti Rissanen, PÄIvi Hietanen, Kaisu Nevasaari & Leena Helle. (1992) FEC (5-Fluorouracil-Epirubicin-Cyclophosphamide) Monthly Versus FEC Weekly in Metastatic Breast Cancer: First results of a randomized trial. Acta Oncologica 31:2, pages 231-236.
Read now
Read now
S. C. A. Fraser, S. R. Ebbs, H. J. Dobbs, L. J. Fallowfield & M. Baum. (1990) The Design of Advanced Breast Cancer Trials New approaches. Acta Oncologica 29:3, pages 397-400.
Read now
Read now
Articles from other publishers (17)
Davide Mauri, Nikolaos P. Polyzos, Georgia Salanti, Nicholas Pavlidis & John P. A. Ioannidis. (2008) Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer. JNCI: Journal of the National Cancer Institute 100:24, pages 1780-1791.
Crossref
Crossref
Nicholas J. Robert, Charles L. Vogel, I. Craig Henderson, Joseph A. Sparano, Melvin R. Moore, Paula Silverman, Beth A. Overmoyer, Charles L. Shapiro, John W. Park, Gail T. Colbern, Eric P. Winer & Alberto A. Gabizon. (2004) The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars in Oncology 31, pages 106-146.
Crossref
Crossref
Uriel Bohn Sarmiento, Jose Aguiar Morales, David Aguiar Bujanda & Araceli Caballero Hidalgo. (2004) High dose epirubicin and cyclophosphamide in breast cancer stage IIIBEpirrubicina a altas dosis y ciclofosfamida en cáncer de mama IIIB. Clinical and Translational Oncology 6:6, pages 347-352.
Crossref
Crossref
Ian F. Faneyte, Johannes L. Peterse, Harm van Tinteren, Corina Pronk, Elisabeth G. E. de Vries, Sjoerd Rodenhuis & Marc J. van de Vijver. (2004) Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement. Clinical Cancer Research 10:13, pages 4457-4463.
Crossref
Crossref
R.L. Basser. (2001) Optimal dose of chemotherapy in adjuvant treatment of breast cancer. The Breast 10, pages 96-100.
Crossref
Crossref
M. Stockler, N.R.C. Wilcken, D. Ghersi & R.John Simes. (2000) Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews 26:3, pages 151-168.
Crossref
Crossref
G. Fountzilas, A. Athanassiades, T. Giannakakis, E. Briasoulis, D. Bafaloukos, A. Kalogera-Fountzila, A. Onienaoum, H. Kalofonos, D. Pectasides, E. Andreopoulou, C. Bamia, P. Kosmidis, N. Pavlidis & D. Skarlos. (1997) A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Annals of Oncology 8:12, pages 1213-1220.
Crossref
Crossref
M.E.L. van der Burg, G. Bolis, J.M. Bakker, D. Curran, T. Sahmoud & J.B. Vermerken. (1997) Phase II study of weekly 4′-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC gynaecological cancer cooperative group study. European Journal of Cancer 33:9, pages 1513-1515.
Crossref
Crossref
Charles Hesdorffer, Karen Antman, Arthur Bank, Michael Fetell, Gregory Mears & Melissa Begg. (1994) Human MDR Gene Transfer in Patients with Advanced Cancer. Columbia University, New York, New York. Human Gene Therapy 5:9, pages 1151-1160.
Crossref
Crossref
Arno J. Mundt, Gregory S. Sibley, Stephanie Williams, Steven J. Rubin, Ruth Heimann, Howard Halpern & Ralph R. Weichselbaum. (1994) Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: Implications for the use of adjuvant radiation therapy. International Journal of Radiation Oncology*Biology*Physics 30:1, pages 151-160.
Crossref
Crossref
G. Fountzilas, D. Skarlos, T. Giannakakis, A. Athanasiades, D. Bafaloukos, A. Kalogera-Fountzila, C. Bamia, N. Pavlidis & P. Kosmidis. (1994) Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancer. European Journal of Cancer 30:7, pages 965-969.
Crossref
Crossref
Karmen Wong & I. Craig Henderson. (1994) Management of metastatic breast cancer. World Journal of Surgery 18:1, pages 98-111.
Crossref
Crossref
M. VENTURINI, L. MASTRO, A. ARDIZZONI, M. R. SERTOLI, G. L. MARIANI, M. C. PENNUCCI, O. GARRONE, S. SILVESTRO, G. F. ADDAMO, P. QUEIROLO & R. ROSSO. (1993) High Dose Intensity Chemotherapy without Bone Marrow Support: Role of Granulocyte-Macrophage Colony-Stimulating Factor. Annals of the New York Academy of Sciences 698:1 Breast Cancer, pages 389-397.
Crossref
Crossref
A. Paul Launchbury & Nassir Habboubi. (1993) Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treatment Reviews 19:3, pages 197-228.
Crossref
Crossref
K. Mross, C. Bohn, L. Edler, W. Jonat, W. Queisser, E. Heidemann, M. Goebel & D.K. Hossfeld. (1993) Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer. Annals of Oncology 4:1, pages 45-50.
Crossref
Crossref
M.E.L. van der Burg, S. Monfardini, J.P. Guastalla, C. de Oliveira, J. Renard & J.B. Vermorken. (1993) Phase II study of weekly 4′-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: An EORTC Gynaecological Cancer Cooperative Group Study. European Journal of Cancer 29:1, pages 147-148.
Crossref
Crossref
M. Bontenbal, A. S. Th. Planting, C. J. Rodenburg, A. Dees, J. Verweij, C. C. M. Bartels, J. Alexieva-Figusch, W. L. J. van Putten & J. G. M. Klijn. (1992) Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment 21:2, pages 133-138.
Crossref
Crossref